Microbial and Systemic Effects of SNAC-Enabled Oral Semaglutide Administration
February 20, 2026
Brand Name :
Synvisc
Synonyms :
hylan g-f 20
Class :
Viscosupplementation agents, Intra-articular agents, and cross-linked hyaluronic acid derivatives
Dosage Forms & Strengths
Injectable solution (intra-articular)
16 mg/2 mL
48 mg/6 mL
Age: > 21
16 mg into the knee once a week for three weeks
Safety and efficacy are not studied
Refer to the adult dosing
Actions and Spectrum:
It enhances the knee synovial fluid capacity to absorb shock and restores which reduces discomfort.
It also lessens gastrointestinal adverse effects and helps delay knee replacement surgery.
Frequency not defined
Pain
Nausea
Muscle pain
Paresthesia
Infection of the joint
Tachycardia
Peripheral edema
Tiredness
Generalized urticaria
Tonsillitis
Hemorrhoids
Black Box Warning:
It shows serious adverse events.
Contraindication/Caution:
Contraindications
Hypersensitivity
Cautions
Renal impairment
Blood clotting disorder
Pregnancy Warnings:
Pregnancy category: Not assigned
Lactation:
Excretion of the drug into human breast milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
<b>Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
It is a viscosupplementation treatment for knee pain due to osteoarthritis.
Pharmacodynamics:
It consists of hylan A fluid, hylan B gel, and saltwater derived from hyaluronan found in chicken combs. The treatment aims to replace damaged synovial fluid with a substance resembling that in healthy joints in 18- to 27-year-olds.
Pharmacokinetics:
Elimination and Excretion
half-life is 7.88.8 days
Administration:
The route of administration is intraarticular given for three weeks requires careful aseptic approach. In order to prevent using the same syringe for both injections, synovial fluid must be removed using an 18-22 gauge needle prior to each injection.
Patient information leaflet
Generic Name: hylan g-f 20
Pronounced: HIGH-lan jee eff twen-tee
Why do we use hylan g-f 20?
Hylan G-F 20 treats osteoarthritis in the knee disorder marked by a reduction in synovial fluid helps to enhance joint functionality, reduce discomfort, and increase mobility.